Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 126.35
AVDL's Cash-to-Debt is ranked higher than
52% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. AVDL: 126.35 )
Ranked among companies with meaningful Cash-to-Debt only.
AVDL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 10.12 Max: 216.7
Current: 126.35
0.08
216.7
Equity-to-Asset 0.35
AVDL's Equity-to-Asset is ranked lower than
81% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AVDL: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
AVDL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.49 Max: 0.8
Current: 0.35
-0.32
0.8
Debt-to-Equity 0.01
AVDL's Debt-to-Equity is ranked higher than
100% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 0.26 vs. AVDL: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
AVDL' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.99  Med: 0.06 Max: 10.98
Current: 0.01
-8.99
10.98
Debt-to-EBITDA 0.01
AVDL's Debt-to-EBITDA is ranked higher than
100% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. AVDL: 0.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AVDL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.98  Med: -0.72 Max: 0.14
Current: 0.01
-5.98
0.14
Interest Coverage 105.38
AVDL's Interest Coverage is ranked lower than
72% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AVDL: 105.38 )
Ranked among companies with meaningful Interest Coverage only.
AVDL' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 105.38
Current: 105.38
0
105.38
Altman Z-Score: 2.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 60.94
AVDL's Operating Margin % is ranked higher than
98% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. AVDL: 60.94 )
Ranked among companies with meaningful Operating Margin % only.
AVDL' s Operating Margin % Range Over the Past 10 Years
Min: -1285  Med: -31.77 Max: 60.94
Current: 60.94
-1285
60.94
Net Margin % 44.75
AVDL's Net Margin % is ranked higher than
95% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. AVDL: 44.75 )
Ranked among companies with meaningful Net Margin % only.
AVDL' s Net Margin % Range Over the Past 10 Years
Min: -1027.16  Med: -29.38 Max: 44.75
Current: 44.75
-1027.16
44.75
ROE % 130.55
AVDL's ROE % is ranked higher than
99% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: -39.05 vs. AVDL: 130.55 )
Ranked among companies with meaningful ROE % only.
AVDL' s ROE % Range Over the Past 10 Years
Min: -1111.21  Med: -25.52 Max: 130.55
Current: 130.55
-1111.21
130.55
ROA % 31.52
AVDL's ROA % is ranked higher than
98% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. AVDL: 31.52 )
Ranked among companies with meaningful ROA % only.
AVDL' s ROA % Range Over the Past 10 Years
Min: -58.85  Med: -12.4 Max: 31.52
Current: 31.52
-58.85
31.52
ROC (Joel Greenblatt) % 3258.69
AVDL's ROC (Joel Greenblatt) % is ranked higher than
99% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. AVDL: 3258.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVDL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1801.54  Med: -42.79 Max: 3538.48
Current: 3258.69
-1801.54
3538.48
3-Year Revenue Growth Rate 181.10
AVDL's 3-Year Revenue Growth Rate is ranked higher than
97% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AVDL: 181.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AVDL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -52.4  Med: 0.35 Max: 181.1
Current: 181.1
-52.4
181.1
3-Year EPS without NRI Growth Rate -18.20
AVDL's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. AVDL: -18.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AVDL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.2  Med: -18.2 Max: 90
Current: -18.2
-38.2
90
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVDL's 30-Y Financials

Financials (Next Earnings Date: 2018-03-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

AVDL Guru Trades in Q1 2017

Jim Simons 11,900 sh (New)
» More
Q2 2017

AVDL Guru Trades in Q2 2017

Jim Simons 698,273 sh (+5767.84%)
» More
Q3 2017

AVDL Guru Trades in Q3 2017

Jim Simons 823,700 sh (+17.96%)
» More
Q4 2017

AVDL Guru Trades in Q4 2017

Charles Brandes 3,308,250 sh (New)
Jim Simons 1,144,600 sh (+38.96%)
» More
» Details

Insider Trades

Latest Guru Trades with AVDL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2017-12-31 New Buy0.55%$8.03 - $11.25 $ 7.74-17%3,308,250
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412 
Compare:LSE:HZD, NAS:PGNX, TSX:TH, LSE:OXB, NAS:AKAO, NAS:BCRX, XKRX:174900, NAS:INO, SZSE:300705, NAS:MLNT, TSX:AUP, XMCE:PHM, OSTO:WTX, NAS:CCXI, OCSE:ZEAL, NAS:PDLI, NAS:SVA, NAS:TYME, NAS:MCRB, AMEX:XXII » details
Traded in other countries:AWK1.Germany,
Headquarter Location:Ireland
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company developing and commercializing pharmaceutical products. The company's products include Bloxiverz, Vazculep, Akovaz, Karbinal ER, AcipHex Sprinkle, Cefaclor and Flexichamber.

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.

Top Ranked Articles about Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals Announces Pricing of $125.0 Million 4.50% Exchangeable Senior Notes due 2023
Avadel Pharmaceuticals Announces Proposed Exchangeable Senior Notes Offering
Charles Brandes Subscribes to Comcast in 4th Quarter Graham disciple's top three buys include two health care companies
Charles Brandes (Trades, Portfolio), chairman of Brandes Investment Partners, invests in companies using a Graham-style approach. During fourth-quarter 2017, the guru initiated 45 new positions, including Comcast Corp. (NASDAQ:CMCSA). Brandes' top three buys are Celestica Inc. (NYSE:CLS), Avadel Pharmaceuticals PLC (NASDAQ:AVDL) and Edgewell Personal Care Co. (NYSE:EPC). Read more...
Avadel Pharmaceuticals Announces Divestiture of Pediatric Business
Avadel Pharmaceuticals Announces Divestiture of Pediatric Business
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for FT 218 for the Treatment of Narcolepsy
Avadel Pharmaceuticals Issues 2018 Corporate Outlook
Avadel Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
Avadel Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
Avadel Pharmaceuticals to Host Analyst and Investor Meeting

Ratios

vs
industry
vs
history
PE Ratio 3.99
AVDL's PE Ratio is ranked higher than
90% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 28.26 vs. AVDL: 3.99 )
Ranked among companies with meaningful PE Ratio only.
AVDL' s PE Ratio Range Over the Past 10 Years
Min: 3.93  Med: 11.86 Max: 33.65
Current: 3.99
3.93
33.65
PE Ratio without NRI 3.99
AVDL's PE Ratio without NRI is ranked higher than
91% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. AVDL: 3.99 )
Ranked among companies with meaningful PE Ratio without NRI only.
AVDL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 3.93  Med: 11.86 Max: 33.65
Current: 3.99
3.93
33.65
Price-to-Owner-Earnings 6.00
AVDL's Price-to-Owner-Earnings is ranked higher than
87% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 35.22 vs. AVDL: 6.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AVDL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.91  Med: 20.93 Max: 537.22
Current: 6
5.91
537.22
PB Ratio 3.34
AVDL's PB Ratio is ranked higher than
53% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AVDL: 3.34 )
Ranked among companies with meaningful PB Ratio only.
AVDL' s PB Ratio Range Over the Past 10 Years
Min: 1.84  Med: 4.81 Max: 71.87
Current: 3.34
1.84
71.87
PS Ratio 1.78
AVDL's PS Ratio is ranked higher than
86% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. AVDL: 1.78 )
Ranked among companies with meaningful PS Ratio only.
AVDL' s PS Ratio Range Over the Past 10 Years
Min: 1.75  Med: 4.76 Max: 799.47
Current: 1.78
1.75
799.47
Price-to-Operating-Cash-Flow 8.62
AVDL's Price-to-Operating-Cash-Flow is ranked higher than
82% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 26.94 vs. AVDL: 8.62 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AVDL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.79  Med: 16.25 Max: 49.71
Current: 8.62
4.79
49.71
EV-to-EBIT 1.80
AVDL's EV-to-EBIT is ranked higher than
92% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. AVDL: 1.80 )
Ranked among companies with meaningful EV-to-EBIT only.
AVDL' s EV-to-EBIT Range Over the Past 10 Years
Min: -88.3  Med: -8.3 Max: 13.8
Current: 1.8
-88.3
13.8
EV-to-EBITDA 1.69
AVDL's EV-to-EBITDA is ranked higher than
92% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. AVDL: 1.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVDL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -314.7  Med: -9.55 Max: 76.3
Current: 1.69
-314.7
76.3
EV-to-Revenue 1.05
AVDL's EV-to-Revenue is ranked higher than
94% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. AVDL: 1.05 )
Ranked among companies with meaningful EV-to-Revenue only.
AVDL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 4.25 Max: 248
Current: 1.05
1.1
248
Current Ratio 1.53
AVDL's Current Ratio is ranked lower than
80% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AVDL: 1.53 )
Ranked among companies with meaningful Current Ratio only.
AVDL' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.77 Max: 6.76
Current: 1.53
0.57
6.76
Quick Ratio 1.47
AVDL's Quick Ratio is ranked lower than
77% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. AVDL: 1.47 )
Ranked among companies with meaningful Quick Ratio only.
AVDL' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2.63 Max: 6.7
Current: 1.47
0.52
6.7
Days Inventory 118.96
AVDL's Days Inventory is ranked higher than
53% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. AVDL: 118.96 )
Ranked among companies with meaningful Days Inventory only.
AVDL' s Days Inventory Range Over the Past 10 Years
Min: 51.05  Med: 84.53 Max: 1457.72
Current: 118.96
51.05
1457.72
Days Sales Outstanding 48.40
AVDL's Days Sales Outstanding is ranked higher than
64% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. AVDL: 48.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVDL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.8  Med: 69.78 Max: 541.87
Current: 48.4
15.8
541.87
Days Payable 210.58
AVDL's Days Payable is ranked higher than
83% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 59.19 vs. AVDL: 210.58 )
Ranked among companies with meaningful Days Payable only.
AVDL' s Days Payable Range Over the Past 10 Years
Min: 161.48  Med: 228.67 Max: 3311.63
Current: 210.58
161.48
3311.63

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.30
AVDL's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. AVDL: -17.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVDL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47.7  Med: -7.8 Max: -0.5
Current: -17.3
-47.7
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.12
AVDL's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
54% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.39 vs. AVDL: 3.12 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AVDL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.74  Med: 6.44 Max: 96.31
Current: 3.12
2.74
96.31
Price-to-Median-PS-Value 0.38
AVDL's Price-to-Median-PS-Value is ranked higher than
82% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. AVDL: 0.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AVDL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 1.2 Max: 166.67
Current: 0.38
0.31
166.67
Earnings Yield (Greenblatt) % 55.34
AVDL's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. AVDL: 55.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVDL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.8  Med: -7.5 Max: 56.75
Current: 55.34
-26.8
56.75

More Statistics

Revenue (TTM) (Mil) $181.58
EPS (TTM) $ 1.93
Beta2.20
Short Percentage of Float0.00%
52-Week Range $7.52 - 12.30
Shares Outstanding (Mil)39.76 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 173 118 134 217
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 0.32 -1.30 -0.75 0.50
EPS without NRI ($) 0.32 -1.30 -0.75 0.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}